Share on StockTwits

Equities researchers at Credit Suisse initiated coverage on shares of VIVUS (NASDAQ:VVUS) in a research report issued on Thursday. The firm set a “neutral” rating on the stock.

VIVUS (NASDAQ:VVUS) traded up 0.15% during mid-day trading on Thursday, hitting $4.2165. The stock had a trading volume of 321,525 shares. VIVUS has a 52-week low of $4.06 and a 52-week high of $11.98. The stock has a 50-day moving average of $4.50 and a 200-day moving average of $5.1. The company’s market cap is $436.2 million.

VIVUS (NASDAQ:VVUS) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.03. The company had revenue of $21.90 million for the quarter, compared to the consensus estimate of $17.90 million. During the same quarter in the previous year, the company posted ($0.55) earnings per share. The company’s revenue for the quarter was up 298.2% on a year-over-year basis. On average, analysts predict that VIVUS will post $-1.01 earnings per share for the current fiscal year.

VIVUS, Inc is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.